AstraZeneca and Amgen announced positive phase 3 results for Tezspire in treating eosinophilic esophagitis, a chronic inflammatory disorder affecting over 470,000 people in the U.S.
The experimental therapy, a monoclonal antibody that inhibits the TSLP protein, demonstrated efficacy in reducing inflammation linked to eosinophil-driven conditions. Tezspire is already approved for severe asthma and is being evaluated for additional indications.
The late-stage trial success follows a setback for AstraZeneca’s pipeline in July, when its heart disease drug Wainua failed a trial and a late-stage study of Ultomiris also missed primary endpoints. In May, a U.S. regulatory panel rejected camizestrant due to trial design concerns, and AstraZeneca halted an advanced study of its experimental lung cancer drug volrustomig this month.
Tezspire generated $1.13 billion in sales for AstraZeneca in 2025, contributing to the company’s push toward an $80 billion annual revenue target by 2030. The drug is positioned as a potential rival to Dupixent, Sanofi and Regeneron’s blockbuster treatment for similar inflammatory conditions.
AstraZeneca’s shares were down 0.5% at 0729 GMT on Thursday, extending a 14% decline since the Wainua trial failure. The company remains focused on advancing its pipeline amid mixed clinical outcomes.
